The immediate $55M draw strengthens the balance sheet and removes near-term distress risk. The real catalyst is FDA approval of Anaphylm by Dec 31, 2027 — that unlocks the $20M Tranche B and begins the net sales covenant testing. The shelf registration filed simultaneously raises potential for equity dilution. Watch for detailed terms of the shelf offering and any insider selling post-closing.
Price Chart
Executive Summary
Aquestive Therapeutics filed an S-3 shelf registration statement, but the primary event in this filing is the entry into a $150,000,000 senior secured term loan facility with Oaktree on May 12, 2026. The facility consists of a $55,000,000 Tranche A funded at close, followed by up to $95,000,000 in delayed-draw tranches (Tranches B, C, D) tied to FDA approval of Anaphylm (by Dec 31, 2027) and net sales milestones. Tranche B ($20M) requires FDA approval of Anaphylm by Dec 31, 2027. The loan carries a 6.25% margin over 3-month Term SOFR (floor 2.75%), maturity May 12, 2031, and includes a minimum liquidity covenant ($27.5M pre-Tranche B, $15M post-Tranche B) and a minimum net sales covenant beginning in Q4 2027. Proceeds repay the existing credit facility (Existing Credit Facility) and for general corporate purposes. This refinancing from existing debt and a potential future equity sale via the shelf. The loan is secured by substantially all assets, including IP. The shelf registration was filed concurrently, indicating potential future equity issuance.
Key Facts
- Aquestive enters a $150M senior secured term loan facility with Oaktree (administrative agent).
- Tranche A of $55M funded at closing on May 12, 2026.
- Tranche B of $20M requires FDA approval of Anaphylm (NDA #219870) by Dec 31, 2027.
- Tranche C of $25M requires $20M+ in trailing 6-month net sales after Tranche B funding.
- Tranche D of $50M is subject to lender consent additional terms.
- Interest rate = 6.25% margin + 3-month Term SOFR (floor 2.75%), PIK option on up to 200bps until 2nd anniversary.
- Maturity: May 12, 2031.
- Minimum liquidity covenant: $27.5M before Tranche B funding, $15M after.
- Minimum net sales covenant begins Q4 2027 (12-month rolling net sales test), with cure rights.
- Proceeds used to repay existing credit facility and for general corporate purposes.
- Loan secured by substantially all assets (including IP) via Security Agreement.
- S-3 shelf registration filed concurrently — enables future equity or other securities offerings.
Financial Impact
$150M senior secured term loan facility; $55M drawn at close; up to $95M additional contingent on FDA approval and sales milestones.
Risk Factors
- If FDA approval of Anaphylm is not obtained by Dec 31, 2027, the mandatory prepayment trigger (Specified Repayment) of up to Minimum Liquidity Amount applies.
- Net sales covenant (starting Q4 2027) with only 4 cure periods over the loan term creates performance pressure.
- S-3 shelf creates overhang for potential equity issuance — dilution risk for common shareholders.
- PIK interest option delays cash interest but capitalizes principal, increasing debt burden.
- Cross-filing context with prior 10-Q indicates the company needed this refinancing, not just opportunistic — 10-Q shows ongoing ATM program usage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-026568 |
| Document: ny20076831x1_ex10-3.htm | 0001140361-26-026568 |
| Document: ny20076831x1_s3.htm | 0001140361-26-026568 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.09%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.09%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.77%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−13.96%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+13.96%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.88%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.06%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.70%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.53%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers